Hashimoto’s encephalopathy is a rare, immune-mediated brain condition linked to high levels of thyroid antibodies in the blood. Its estimated prevalence is about 2.1 per 100,000 people. Despite the name, the condition is not caused by thyroid dysfunction itself. Instead, the immune system appears to attack the brain, producing neurological and psychiatric symptoms that can mimic stroke, dementia, or psychosis. The good news: it typically responds well to steroid treatment, which is why many specialists now prefer the name “steroid-responsive encephalopathy associated with autoimmune thyroiditis,” or SREAT.
Why the Name Is Misleading
The term “Hashimoto’s encephalopathy” suggests the condition is a direct complication of Hashimoto’s thyroiditis, the common autoimmune thyroid disease. That’s not quite right. Many people diagnosed with this encephalopathy have normal thyroid hormone levels at the time their neurological symptoms appear. Their thyroid may be functioning fine. What connects the two conditions is the presence of anti-thyroid antibodies, specifically anti-TPO (thyroid peroxidase) antibodies, circulating at high levels. But the brain symptoms don’t come from having too much or too little thyroid hormone. They come from an immune process that isn’t fully understood yet.
This is why a growing number of neurologists use the term SREAT instead. It shifts the focus to what actually defines the condition: brain inflammation in someone with thyroid antibodies, where symptoms improve dramatically with steroids. The name also helps distinguish it from the cognitive sluggishness that can happen with hypothyroidism, which is a completely different problem with a different treatment.
Who Gets It
Hashimoto’s encephalopathy affects women about four times as often as men, consistent with the pattern seen in most autoimmune conditions. The average age of onset is 44, with most cases diagnosed during a person’s 40s or 50s. That said, roughly 20% of cases appear before age 18, so it is not exclusively an adult condition.
Symptoms and How They Present
The hallmark of this condition is a subacute onset of confusion with an altered level of consciousness. “Subacute” means symptoms develop over days to weeks rather than hitting all at once like a stroke or building slowly over years like Alzheimer’s. The most common presentation is cognitive impairment: difficulty thinking clearly, trouble with memory, problems finding words, or a general mental fogginess that worsens noticeably over a short period.
Seizures are strikingly common, occurring in an estimated 47% to 70% of patients. These can be focal (affecting one part of the body) or generalized, and they often don’t respond well to standard seizure medications, which can be a clue pointing toward the diagnosis. Up to 25% of patients experience stroke-like episodes, with sudden weakness, numbness, or difficulty speaking that mimics a vascular stroke but shows no evidence of blocked blood flow on imaging.
Psychiatric symptoms round out the picture and are a major reason this condition gets misdiagnosed. People may develop personality changes, paranoia, hallucinations, delusions, or mood swings that look like a primary psychiatric disorder. Catatonia, where a person becomes unresponsive and physically rigid, has also been reported. Sleep disturbances and involuntary muscle jerking (myoclonus) are common as well. Some patients develop problems with coordination and balance, and a smaller number experience sensory symptoms like tingling or numbness.
The combination of cognitive decline, seizures, psychiatric changes, and movement problems in someone who was previously well is the pattern that should raise suspicion, particularly if standard neurological workups aren’t revealing a clear cause.
How It Is Diagnosed
There is no single test that confirms Hashimoto’s encephalopathy. It is a diagnosis of exclusion, meaning other causes of brain inflammation and cognitive decline need to be ruled out first. Viral encephalitis, autoimmune encephalitis from other antibodies, Creutzfeldt-Jakob disease, brain tumors, and vascular problems all need to be considered and eliminated.
The key laboratory finding is elevated anti-TPO antibodies in the blood. These are the same antibodies tested for when diagnosing Hashimoto’s thyroiditis, but in encephalopathy cases, the levels tend to be particularly high. Importantly, thyroid hormone levels themselves may be completely normal. Thyroid dysfunction is not required for the diagnosis, and if thyroid levels are normal, thyroid hormone replacement isn’t part of the treatment.
Brain MRI results are often nonspecific. Some patients show scattered areas of abnormal signal, but many have entirely normal imaging, which can throw clinicians off. EEG (a test measuring electrical activity in the brain) typically shows generalized slowing, a pattern that indicates the brain isn’t functioning normally but doesn’t point to one specific disease. Spinal fluid analysis sometimes reveals mildly elevated protein levels. None of these findings alone clinch the diagnosis. It’s the combination of the clinical picture, high anti-TPO antibodies, exclusion of other causes, and ultimately a positive response to steroids that confirms the condition.
A recent literature review illustrates how difficult diagnosis can be. Researchers screening over 2,700 patients with positive anti-thyroid antibodies found 227 with associated neurological symptoms, but only 12 of those actually met strict diagnostic criteria for Hashimoto’s encephalopathy. The condition is genuinely rare, and the antibodies alone are not enough to make the diagnosis since anti-TPO antibodies are common in the general population, particularly among women.
Treatment and Response
High-dose steroids are the first-line treatment. This typically begins with intravenous steroids given over three to five days in a hospital setting, followed by a transition to oral steroids that are gradually tapered over weeks to months. The goal is to suppress the immune response attacking the brain.
The response to steroids is often dramatic and serves as the defining feature of this condition. Many patients show significant improvement within days of starting treatment, though the full timeline varies. Some people recover almost completely, while others improve but retain some residual cognitive effects. Relapses can occur, especially if steroids are tapered too quickly, and some patients need long-term low-dose steroid therapy or other immune-suppressing medications to stay in remission.
For patients who don’t respond adequately to steroids, or who can’t tolerate them, other immune therapies are sometimes used. These are borrowed from the broader toolkit for autoimmune neurological diseases and are tailored to the individual case.
Why Early Recognition Matters
The single most important thing about Hashimoto’s encephalopathy is that it is treatable. A person who appears to be rapidly declining with dementia-like symptoms, psychosis, or unexplained seizures may have a condition that responds remarkably well to steroids, but only if someone thinks to check for thyroid antibodies and considers this diagnosis. The symptoms overlap with conditions that carry much worse prognoses, from degenerative brain diseases to aggressive psychiatric disorders. Getting the right diagnosis changes the trajectory entirely.
Because the condition is rare and the symptoms are nonspecific, it is frequently missed or delayed. If someone you know is experiencing a rapid, unexplained decline in thinking, personality changes, or new seizures, and standard workups aren’t providing answers, Hashimoto’s encephalopathy is worth raising with the medical team. A simple blood test for anti-TPO antibodies can open the door to a diagnosis that makes a real difference.